The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

A new study published in Engineering has identified enolase 2 (ENO2) as a key factor in the lymphatic metastasis of head and ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck ...

Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal ...

New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet need for adults with unresectable or metastatic esophageal squamous cell ...

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ...

The greater the number of risk factors in patients with cutaneous squamous cell carcinoma, the higher the likelihood of poor ...

The reported risk for metastasis in squamous cell carcinomas (SCCs) ranges from 0.5% to 16%, a wide spread that can probably be explained by differences in patient populations. Identifying the ...

The FDA has approved Tevimbra with chemotherapy for the first-line treatment of unresectable or metastatic ESCC whose tumors express PD-L1.